Acetazolamide for Treating NPH in Shunt-candidates Patients

Status Recruiting

Clinical Trial Summary

Normal pressure hydrocephalus (NPH) consists of a triad of gait disturbance, cognitive deterioration, and urinary incontinence and is characterized by enlarged cerebral ventricles. Current treatment recommendations are based on surgical diversion of Cerebrospinal fluid (CSF), by a ventriculoperitoneal shunt. When patients are appropriately selected, shunting for NPH has a sustained effect in one-half to two-thirds of patients with a reasonable complication rate. However, evidence regarding the efficacy of shunt surgery consists largely of observational studies with relatively short-term follow-up.

With regards to the adverse effects of shunting, even though decreased substantially in recent years, shunt complications are still common. Recent studies report ten to twenty-two percent of serious adverse effects following shunt surgery, mainly subdural hematoma (SDH) requiring surgery, infection, and cerebral infarction or hemorrhage. Most complication occur in the first year after the procedure. Many others suffer from adverse events that considered non-serious, such as postural headache and asymptomatic SDH.

Since shunt complications are common and potentially severe, there is a need for a better way to identify those patients that will likely benefit from shunting, and find alternative treatments for those unwilling or unable to withstand surgery.

Acetazolamide has been shown to reduce the production of CSF in clinical cases of raised intracranial pressure. It is considered the drug of choice for the treatment of idiopathic intracranial hypertension (pseudotumor cerebri). Intuitively, acetazolamide can be effective for the treatment of NPH by reducing the volume of CSF in the brain, and serve as a medical alternative to shunting. Few case reports and small series demonstrated improvement in MRI abnormalities in NPH-patients after administrating the medication.

This open-label study will examine the feasibility and effectiveness of acetazolamide in NPH-diagnosed patients who are shunt-candidates. Patients will be treated from time of diagnosis, and gait and cognition will be evaluated after 2-6 weeks. This trial would possibly pave the way to a larger randomized placebo-controlled trials, and perhaps offer a medical alternative to surgery for elderly patients and for patients for which operation is contraindicated.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03779594
Study type	Interventional
Source	Rabin Medical Center
Contact	Gilad Kenan, MD
Phone	97289779181
Email	giladankori@gmail.com
Status	Recruiting
Phase	Phase 2
Start date	December 2018
Completion date	December 2019

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT00149721` - Anterior Pituitary Function in Patients With Hydrocephalus	N/A
Completed	`NCT00196196` - A Precision and Accuracy Study of the Codman Valve Position Verification (VPV) System.	Phase 3
Not yet recruiting	`NCT05562596` - Normal Pressure Hydrocephalus Biomarkers Investigation
Completed	`NCT00233701` - Normal Pressure Hydrocephalus (NPH) Registry	Phase 4
Unknown status	`NCT00874198` - European Study on Prediction of Outcome in Patients With Idiopathic Normal Pressure Hydrocephalus	N/A
Withdrawn	`NCT00793416` - ShuntCheck Accuracy in Detecting Shunt Obstruction Normal Pressure Hydrocephalus (NPH) Patients	Phase 4
Recruiting	`NCT05910944` - European Study of Prodromal iNPH
Active, not recruiting	`NCT01909960` - Flow MRI in Normal Pressure Hydrocephalus	N/A
Completed	`NCT02016352` - Cerebrospinal Fluid Proteome in Hydrocephalus	N/A
Terminated	`NCT01092546` - Positron Emission Tomography Imaging of Brain Amyloid in Normal Pressure Hydrocephalus	Phase 3
Terminated	`NCT00613886` - Factors Predicting Response to Shunting in Normal Pressure Hydrocephalus	N/A
Completed	`NCT01815775` - Predictive Value of Flow MRI in Normal Pressure Hydrocephalus Surgery	Phase 0
Recruiting	`NCT03877107` - Effect of Depletive Lumbar Puncture on Lower Urinary Tract Dysfunction in iNPH	N/A
Enrolling by invitation	`NCT03269201` - Brain Network Activation in Patients With Movement Disorders
Recruiting	`NCT03245138` - Endoscopic Third Ventriculostomy Versus Ventriculo-peritoneal Shunting in Idiopathic Normal Pressure Hydrocephalus	N/A
Terminated	`NCT00727142` - Conservative Versus Surgical Management of Idiopathic Normal Pressure Hydrocephalus (INPH)	N/A
Recruiting	`NCT04471740` - Normal Pressure Hydrocephalus and Sleep Apnea	N/A
Completed	`NCT01798641` - A Randomized Cross-over Study for Normal Pressure Hydrocephalus	N/A
Recruiting	`NCT01618500` - Computerised Testing of Cognitive Response to Cerebrospinal Fluid Shunting in Idiopathic Normal Pressure Hydrocephalus	N/A
Completed	`NCT00600795` - Prognostic Value of Transforming Growth Factor-Beta 1 in Normal Pressure Hydrocephalus	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.